文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

密码子特异性KRAS突变预测转移性结直肠癌中曲氟尿苷/替匹嘧啶的生存获益

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
PubMed 文献 · Nat Med · 2023-03-02

研究通过37例转移性结直肠癌(mCRC)患者全基因组分析发现KRASG12突变可能是FTD/TPI耐药标志物,并在960例真实世界数据和800例RECOURSE 3期试验中验证。RECOURSE中KRASG12突变患者(n=279)接受FTD/TPI vs 安慰剂的总生存(OS)无显著延长(HR=0.97,95%CI 0.73-1.20,P=0.85),而KRASG13突变患者(n=60)OS显著改善(HR=0.29,95%CI 0.15-0.55,P<0.001)。

要点

  • KRASG12突变是mCRC患者FTD/TPI治疗OS获益降低的预测标志物。
  • RECOURSE试验中KRASG12突变患者FTD/TPI vs 安慰剂OS无显著延长(HR=0.97,95%CI 0.73-1.20,P=0.85)。
  • KRASG13突变患者FTD/TPI vs 安慰剂OS显著改善(HR=0.29,95%CI 0.15-0.55,P<0.001)。

核心结论

  • KRASG12突变是mCRC患者FTD/TPI治疗OS获益降低的生物标志物,可能影响约28%考虑接受FTD/TPI治疗的mCRC患者。
  • 数据提示基于基因组学的精准医学可能适用于部分化疗药物。

研究设计与样本

  • 对37例接受FTD/TPI治疗的mCRC患者进行全基因组分析。
  • 收集960例接受FTD/TPI治疗的mCRC患者真实世界数据进行验证。
  • 分析全球、双盲、安慰剂对照的3期RECOURSE试验(n=800例患者)数据。

主要发现

  • 在37例患者全基因组分析中鉴定KRASG12突变为耐药潜在生物标志物。
  • 960例真实世界数据验证KRASG12突变与较差生存显著相关,在仅限RAS/RAF突变亚组分析中亦如此。
  • RECOURSE试验中KRASG12突变(n=279)是FTD/TPI vs 安慰剂OS获益降低的预测生物标志物(未校正交互作用P=0.0031,校正交互作用P=0.015)。
  • RECOURSE试验中KRASG12突变患者(n=279)FTD/TPI vs 安慰剂OS未延长(HR=0.97,95%CI 0.73-1.20,P=0.85)。
  • RECOURSE试验中KRASG13突变肿瘤患者(n=60)FTD/TPI vs 安慰剂OS显著改善(HR=0.29,95%CI 0.15-0.55,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified KRAS codon G12 (KRASG12) mutations as a potential biomarker of resistance. Next, we collected real-world data of 960 patients with mCRC receiving FTD/TPI and validated that KRASG12 mutations were significantly associated with poor survival, also in analyses restricted to the RAS/RAF mutant subgroup. We next analyzed the data of the global, double-blind, placebo-controlled, phase 3 RECOURSE trial (n = 800 patients) and found that KRASG12 mutations (n = 279) were predictive biomarkers for reduced overall survival (OS) benefit of FTD/TPI versus placebo (unadjusted interaction P = 0.0031, adjusted interaction P = 0.015). For patients with KRASG12 mutations in the RECOURSE trial, OS was not prolonged with FTD/TPI versus placebo (n = 279; hazard ratio (HR) = 0.97; 95% confidence interval (CI) = 0.73-1.20; P = 0.85). In contrast, patients with KRASG13 mutant tumors showed significantly improved OS with FTD/TPI versus placebo (n = 60; HR = 0.29; 95% CI = 0.15-0.55; P < 0.001). In isogenic cell lines and patient-derived organoids, KRASG12 mutations were associated with increased resistance to FTD-based genotoxicity. In conclusion, these data show that KRASG12 mutations are biomarkers for reduced OS benefit of FTD/TPI treatment, with potential implications for approximately 28% of patients with mCRC under consideration for treatment with FTD/TPI. Furthermore, our data suggest that genomics-based precision medicine may be possible for a subset of chemotherapies.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. van de Haar J, Ma X, Ooft SN, et al. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nat Med. 2023. PMID: 36864254. doi:10.1038/s41591-023-02240-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。